open access
Presentation, therapy and outcome of patients with ischemic stroke under new oral anticoagulants
Affiliations- Hospital Rudolf-Foundation, Wien, Austria
open access
Abstract
Aim was to describe the clinical spectrum, therapy, and outcome of ischemic strokes under therapy with new oral anticoagulants (NOAC).
Methods and resultsA literature research was carried out in PubMed. Clinical trials as well as case reports were included. Four large trials comparing NOAC with warfarin reported 469 ischemic strokes but neither co-medication, nor comorbidities, location, clinical spectrum, therapy, nor outcome are reported. Eleven cases with ischemic strokes under dabigatran from the literature are reported. Six patients received thrombolytic therapy, in three of them unaware dabigatran therapy. Two patients received mechanical recanalization. Two patients died, one due to cerebral hemorrhage after thrombolysis, the other after partial recanalization of the basilar artery.
ConclusionsLittle is known about ischemic strokes under NOAC. To increase the knowledge, the data of 469 ischemic strokes which occurred in NOAC-investigating trials should be analyzed. Furthermore ischemic and bleeding events under NOAC outside clinical trials should be reported. An international registry, independent from the pharmaceutical industry for collecting these informations is desirable.
Abstract
Aim was to describe the clinical spectrum, therapy, and outcome of ischemic strokes under therapy with new oral anticoagulants (NOAC).
Methods and resultsA literature research was carried out in PubMed. Clinical trials as well as case reports were included. Four large trials comparing NOAC with warfarin reported 469 ischemic strokes but neither co-medication, nor comorbidities, location, clinical spectrum, therapy, nor outcome are reported. Eleven cases with ischemic strokes under dabigatran from the literature are reported. Six patients received thrombolytic therapy, in three of them unaware dabigatran therapy. Two patients received mechanical recanalization. Two patients died, one due to cerebral hemorrhage after thrombolysis, the other after partial recanalization of the basilar artery.
ConclusionsLittle is known about ischemic strokes under NOAC. To increase the knowledge, the data of 469 ischemic strokes which occurred in NOAC-investigating trials should be analyzed. Furthermore ischemic and bleeding events under NOAC outside clinical trials should be reported. An international registry, independent from the pharmaceutical industry for collecting these informations is desirable.
Keywords
Atrial fibrillation, Stroke, Dabigatran, Rivaroxaban, Thrombolysis
About this articleTitle
Presentation, therapy and outcome of patients with ischemic stroke under new oral anticoagulants
Journal
Neurologia i Neurochirurgia Polska
Issue
Article type
Review Article
Pages
136-140
Page views
463
Article views/downloads
314
DOI
10.1016/j.pjnns.2014.03.001
Bibliographic record
Neurol Neurochir Pol 2014;48(2):136-140.
Keywords
Atrial fibrillation
Stroke
Dabigatran
Rivaroxaban
Thrombolysis
Authors
Claudia Stöllberger
Josef Finsterer
